RxDoctor Payments Data

Aaron Estep, DO

Family Medicine · Belpre, OHNPI 1841753936

Payments from drug & device makers

$1,157in general payments, 2019–2025

Across 41 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$405
  • Corcept Therapeutics$244
  • Dexcom, Inc.$111
  • Novo Nordisk$109
  • Boehringer Ingelheim$47
  • Medtronic$44
  • plus $197 from 10 others

What the payments were for

  • Food & beverage$1,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,157 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$6,694
Medicare patients
38
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide83$85,832
TrulicityDulaglutide76$79,074
OzempicSemaglutide54$72,363
JardianceEmpagliflozin53$47,703
JanuviaSitagliptin Phosphate28$20,199
FarxigaDapagliflozin Propanediol21$17,526
Tresiba Flextouch U-100Insulin Degludec16$9,629
BaqsimiGlucagon12$8,614
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$5,579
Insulin Lispro Kwikpen U-100Insulin Lispro27$4,342
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,718
Novolog FlexpenInsulin Aspart11$2,609
Nano 2nd Gen Pen NeedlePen Needle, Diabetic26$1,796
Glimepiride48$550
Metformin Hcl ErMetformin Hcl63$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi$17$173,519171 claims
Novo NordiskOzempic$109$72,36354 claims
Boehringer IngelheimJardiance$47$47,70353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Belpre

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →